SubHero Banner
Text

Synjardy®, Synjardy XR® (empagliflozin/metformin) – Label update

December 23, 2016 – The FDA approved updates to Boehringer Ingelheim’s Synjardy (empagliflozin/metformin) and Synjardy XR (empagliflozin/metformin extended-release) drug labels about the risk reduction of cardiovascular (CV) death with Jardiance<sup>®</sup> (empagliflozin) use.

Download PDF